LYNPARZA

Product Overview

About LYNPARZA

LYNPARZA is a prescription medication containing the active ingredient olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. It is used to treat certain types of cancer, including ovarian cancer and breast cancer.

Key Benefits & Uses

• Treatment of BRCA1/2-mutated advanced ovarian cancer in patients who have been treated with three or more prior lines of chemotherapy.
• Treatment of advanced breast cancer in patients with deleterious or suspected deleterious germline BRCA mutation and who have been previously treated with chemotherapy in the neoadjuvant or adjuvant setting.
• Adjuvant treatment of patients with deleterious or suspected deleterious BRCA1 or BRCA2 mutation-associated triple-negative breast cancer who have received neoadjuvant chemotherapy.

Active Ingredient & Action

OLAPARIB works by inhibiting the activity of PARP enzymes, which are involved in DNA repair. By blocking these enzymes, LYNPARZA prevents cancer cells from repairing their DNA, leading to cell death and slowing the growth of tumors.

Important Notes

LYNPARZA is available in tablet form and should be taken orally. It is essential to follow the recommended dosage and administration instructions provided by your healthcare provider. Common side effects may include nausea, vomiting, fatigue, and diarrhea. Patients with a history of bleeding or blood clotting disorders should use caution when taking LYNPARZA. Consult your healthcare provider for more information on the safe use of LYNPARZA.